(March 20, 2025, Shanghai) Walvax Biotechnology Co., Ltd. ("Walvax", stock code: 300142.SZ) participated in the 6th Vaccine Innovation Forum (VIF) World, taking place March 20-22, 2025, at the Shanghai Marriott Hotel Parkview. The Company is presenting important safety data for its 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) as part of the forum's poster presentation sessions. The Walvax delegation is led by Dr. Shaozhong Dong, Vice Chairman of Walvax. The data being presented comes from a Phase IV clinical trial conducted in China, validating the safety profile of Walvax's single-dose PPSV23 vaccine.

This year's forum convenes under the theme "Vaccines of Future: Bridging Science and Society," which emphasizes the critical connection between scientific advancement and public health implementation.

Mr. Andrew Wong, Senior Advisor to the Board of Directors of Walvax and Board Member of the Developing Countries Vaccine Manufacturers Network (DCVMN), chaired the DCVMN Forum on March 20. During this session, representatives from the global health organization PATH, The Gates Foundation and leading vaccine manufacturing companies across developing countries shared valuable insights about each stakeholder’s key roles to boost innovation and capacity expansion in addressing global health challenges.

VIF World 2025 continues to build on its reputation as a premier international event for vaccine innovation and global health discussions. This year's forum features more than 120 speakers and welcomes over 1,000 international delegates representing more than 30 countries.

About 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23)

23-valent Pneumococcal Polysaccharide Vaccine is indicated for the prevention of pneumococcal diseases caused by the 23 serotypes of Streptococcus pneumoniae in individuals aged ≥ 2 years who are at increased risk of pneumococcal disease. It is the world’s 1^st preservative-free PPSV23. Till date, over 12 million doses of PPSV23 manufactured by Walvax have been distributed worldwide, including China, India, Cote d'Ivoire, Bangladesh, Uzbekistan and the Philippines. It is the only PPSV23 in China with non-inferior data generated from international trials, compared to a widely used peer product, verified by both the pivotal phase III clinical trial in China and a phase III clinical trial in India.

About Walvax

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from conventional vaccines to innovative vaccines. Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 22 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.